A Study of Citrate and Bivalirudin for anticoagulation during Continuous Renal Replacement Therapy (CRRT) in Critically ill Patients with Acute kidney Injury (AKI)

DR RAM MANOHAR LOHIA INSTITUTE OF MEDICAL SCIENCES0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Severe AKI (KDIGO 3 classification) despite optimal resuscitation
•-Urine output of less than 0.3 mL/Kg/hour for 24 hours or more than 24 hours.
•-Less than threefold increase in serum creatinine level compared with baseline valve
•-Serum creatinine 4.0 mg/dl or more than 4.0 mg/dl.
•2.Minimum 3 fold increase in Serum Creatinine level along with clinical decision by clinician.
•3.Intention to provide full intensive care treatment for at least 3 day.
•4.Written informed consent of patient or his legal representatives or the Authorized Representative.
•5.Inclusion due to an emergency situation.

•1.Declined consent from guardian.
•2.Patients with an increased bleeding risk (or) active bleeding due to vascular damage (Ulcer in G.I. tract, Intracranial Hemorrhage, Aneurysm of brain arteries).
•3.Dialysis-dependent chronic kidney insufficiency.
•4.Allergic reaction to one of the anticoagulants.
•5.Need of therapeutic anticoagulation ( aPTT >60s, anti-Xa >0.6IE/mL, INR >2)
•6.AKI caused by Glomerulonephritis, Interstitial Nephritis, Vasculitis or Urinary Tract Obstruction.
•7.Haemolytic Uraemic Syndrome/ Thrombotic Thrombocytopenic Purpura.
•8.Kidney transplant within the last 12 months.
•9.Pregnancy and Nursing period.

发起方

DR RAM MANOHAR LOHIA INSTITUTE OF MEDICAL SCIENCES